VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Chronic HCV Infection of Genotype 1, 4, 5, or 6    │ Chronic HCV Infection of Genotype 1, 4, 5, or 6    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ 18 years of age or older                           │ 18 years of age or older                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of chronic HCV infection, defined as     │ Diagnosis of chronic HCV infection, defined as     │     100 │
│ positive HCV antibody or HCV RNA more than 6       │ positive HCV antibody or HCV RNA more than 6       │         │
│ months prior to screening OR an assessment of      │ months prior to screening OR an assessment of      │         │
│ fibrosis F2 or greater prior to screening          │ fibrosis F2 or greater prior to screening          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ NYHA Class III: Subjects with cardiac disease      │ NYHA Class III: Subjects with cardiac disease      │     100 │
│ resulting in marked limitation of physical         │ resulting in marked limitation of physical         │         │
│ activity. They are comfortable at rest. Less than  │ activity. They are comfortable at rest. Less than  │         │
│ ordinary physical activity causes fatigue,         │ ordinary physical activity causes fatigue,         │         │
│ palpitation, dyspnea, or anginal pain              │ palpitation, dyspnea, or anginal pain              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ NYHA Class IV: Patient with cardiac disease        │ NYHA Class IV: Patient with cardiac disease        │     100 │
│ resulting in inability to carry on any physical    │ resulting in inability to carry on any physical    │         │
│ activity without discomfort. Symptoms of cardiac   │ activity without discomfort. Symptoms of cardiac   │         │
│ insufficiency or of the anginal syndrome may be    │ insufficiency or of the anginal syndrome may be    │         │
│ present even at rest. If any physical activity is  │ present even at rest. If any physical activity is  │         │
│ undertaken, discomfort is increased                │ undertaken, discomfort is increased                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ hospitalized for heart failure in last 12 months   │ hospitalized for heart failure in last 12 months   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ILD criteria: diagnosis of interstitial lung       │ ILD criteria: diagnosis of interstitial lung       │     100 │
│ disease with chronic supplemental oxygen           │ disease with chronic supplemental oxygen           │         │
│ requirement at rest and/or with exertion           │ requirement at rest and/or with exertion           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ OR any FEV1 with chronic supplemental oxygen       │ OR any FEV1 with chronic supplemental oxygen       │     100 │
│ requirement at rest and/or with exertion           │ requirement at rest and/or with exertion           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic HCV Infection with Genotype 2 or 3         │ Chronic HCV Infection with Genotype 2 or 3         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Amiodarone. Subjects previously treated with       │ Amiodarone. Subjects previously treated with       │     100 │
│ amiodarone must have stopped the amiodarone at     │ amiodarone must have stopped the amiodarone at     │         │
│ least 60 days prior to day 1 of SOF/LDV FDC        │ least 60 days prior to day 1 of SOF/LDV FDC        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Carbamazepine, phenytoin, phenobarbital,           │ Carbamazepine, phenytoin, phenobarbital,           │     100 │
│ oxcarbazepine                                      │ oxcarbazepine                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Rifabutin, rifampin or rifapentine                 │ Rifabutin, rifampin or rifapentine                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV regimens containing tenofovir or               │ HIV regimens containing tenofovir or               │     100 │
│ tipranavir/ritonavir                               │ tipranavir/ritonavir                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ St. John's wort                                    │ St. John's wort                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Rosuvastatin                                       │ Rosuvastatin                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have any serious or active medical or psychiatric  │ Have any serious or active medical or psychiatric  │     100 │
│ illness which, in the opinion of the investigator, │ illness which, in the opinion of the investigator, │         │
│ would interfere with subject treatment,            │ would interfere with subject treatment,            │         │
│ assessment, or compliance                          │ assessment, or compliance                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hepatic encephalopathy or variceal      │ History of hepatic encephalopathy or variceal      │     100 │
│ hemorrhage                                         │ hemorrhage                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B surface antigen positive               │ Hepatitis B surface antigen positive               │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of major organ transplantation with an     │ History of major organ transplantation with an     │     100 │
│ existing functional graft                          │ existing functional graft                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of clinically-significant drug allergy to  │ History of clinically-significant drug allergy to  │     100 │
│ nucleoside/nucleotide analogs                      │ nucleoside/nucleotide analogs                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant women or women planning to become         │ Pregnant women or women planning to become         │     100 │
│ pregnant                                           │ pregnant                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are breastfeeding                        │ Women who are breastfeeding                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelets ≤ 50,000/mm3                             │ Platelets = 50,000/mm3                             │      95 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ejection fraction ≤ 30%                            │ ejection fraction = 30%                            │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HCV RNA \> 103 IU/mL at screening                  │ HCV RNA > 103 IU/mL at screening                   │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin (Hb) \< 8 g/dL                          │ Hemoglobin (Hb) < 8 g/dL                           │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total bilirubin \> 3 mg/dl                         │ Total bilirubin > 3 mg/dl                          │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active or recent history (≤ 1 year) of drug or     │ Active or recent history (= 1 year) of drug or     │      98 │
│ alcohol abuse                                      │ alcohol abuse                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Forced expiratory volume (FEV1)\< 30% predicted    │ Forced expiratory volume (FEV1)< 30% predicted     │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ OR any FEV1 with chronic hypercapnia (baseline     │ OR any FEV1 with chronic hypercapnia (baseline     │      99 │
│ partial pressure of arterial carbon dioxide        │ partial pressure of arterial carbon dioxide        │         │
│ \[PaCO2\] \> 45)                                   │ [PaCO2] > 45)                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ alanine aminotransferase (ALT), aspartase          │ alanine aminotransferase (ALT), aspartase          │      99 │
│ aminotransferase (AST), or alkaline phosphatase ≥  │ aminotransferase (AST), or alkaline phosphatase =  │         │
│ 10 times upper limit of normal(ULN)                │ 10 times upper limit of normal(ULN)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe renal impairment creatinine clearance       │ Severe renal impairment creatinine clearance       │      99 │
│ (CrCl), i.e. \< 30 mL/min                          │ (CrCl), i.e. < 30 mL/min                           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ COPD criteria (one of the following)               │ 18 years of age or older                          │      37 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subjects in the advanced heart failure cohort must │ NYHA Class III: Subjects with cardiac disease     │      40 │
│ meet all HCV criteria, and all of the following    │ resulting in marked limitation of physical        │         │
│ criteria                                           │ activity. They are comfortable at rest. Less than │         │
│                                                    │ ordinary physical activity causes fatigue,        │         │
│                                                    │ palpitation, dyspnea, or anginal pain             │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subjects in the advanced lung disease cohort must  │ NYHA Class III: Subjects with cardiac disease     │      41 │
│ have been diagnosed with chronic obstructive       │ resulting in marked limitation of physical        │         │
│ pulmonary disease (COPD) or interstitial lung      │ activity. They are comfortable at rest. Less than │         │
│ disease (ILD) must meet all HCV criteria, and meet │ ordinary physical activity causes fatigue,        │         │
│ the following criteria for COPD or ILD             │ palpitation, dyspnea, or anginal pain             │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Abnormal hematological and biochemical parameters, │ History of hepatic encephalopathy or variceal     │      41 │
│ including                                          │ hemorrhage                                        │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ New York Heart Association (NYHA) Class III or IV  │ History of major organ transplantation with an    │      42 │
│ functional classification                          │ existing functional graft                         │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ 18 years of age or older                          │      42 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Treatment with any of the following agents         │ Pregnant women or women planning to become        │      45 │
│                                                    │ pregnant                                          │         │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 89
Average Levenshtein Ratio of individual lines: 88.8974358974359
OverAll Ratio: 88.94871794871796
